The Alopecia Areata drugs in development market research report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alopecia Areata. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alopecia Areata and features dormant and discontinued products.
GlobalData tracks 46 drugs in development for Alopecia Areata by 43 companies/universities/institutes. The top development phase for Alopecia Areata is phase ii with 13 drugs in that stage. The Alopecia Areata pipeline has 46 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Alopecia Areata pipeline products market are: Epibiotech, Sun Pharmaceutical Industries and AbbVie.
The key targets in the Alopecia Areata pipeline products market include Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK3, and Tyrosine Protein Kinase JAK2.
The key mechanisms of action in the Alopecia Areata pipeline product include Tyrosine Protein Kinase JAK1 Inhibitor with eight drugs in Phase III. The Alopecia Areata pipeline products include seven routes of administration with the top ROA being Topical and ten key molecule types in the Alopecia Areata pipeline products market including Small Molecule, and Monoclonal Antibody.
Alopecia Areata overview
Alopecia areata is an autoimmune condition characterized by unpredictable, patchy hair loss. It occurs when the immune system mistakenly attacks hair follicles, leading to hair loss in small, round patches on the scalp or other parts of the body. In some cases, it can progress to total hair loss (alopecia totalis) or loss of hair on the entire body (alopecia universalis). The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic, environmental, and autoimmune factors. It is thought that the immune activity leads to follicle shrinkage and the eventual interruption of hair growth. Alopecia areata typically presents as smooth, round patches of hair loss on the scalp. It can also affect other hair-bearing areas, such as eyebrows, eyelashes, or beard. In some cases, individuals may experience tingling or mild discomfort in the affected areas.
For a complete picture of Alopecia Areata’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
